Status: Recruiting
Study to Assess Safety and Efficacy of Vactosertib in Adolescents and Adults With Recurrent, Refractory or Progressive Osteosarcoma
MP-VAC-209 is a Phase I/II, open label, single arm, multi-center study to assess safety, tolerability, and antitumor activity of vactosertib as a single agent in adolescents and adults with recurrent, refractory, or progressive osteosarcoma. Vactosertib is given orally, twice a day, to people 12 years of age and older who meet the criteria for study enrollment.
Participants needed: 78
Trial details
Phase: Phase 1, Phase 2Age: 12+Biological sex: AllType: InterventionalSponsor: MedPacto, Inc.Updated: Oct 7, 2026Locations: 7
Eligibility criteria
Subjects may be male or female, with adolescents aged 12 to 17 years and adults... [+8]
Subjects who have moderate or severe cardiovascular disease [+24]